A novel chimeric antigen receptor against prostate stem cell antigen mediates tumor destruction in a humanized mouse model of pancreatic cancer. - Wikidata - awgldk - TriplyDB

A novel chimeric antigen receptor against prostate stem cell antigen mediates tumor destruction in a humanized mouse model of pancreatic cancer.

A novel chimeric antigen receptor against prostate stem cell antigen mediates tumor destruction in a humanized mouse model of pancreatic cancer.

http://www.wikidata.org/entity/Q34729692

about

Adoptive immunotherapy for acute leukemia: New insights in chimeric antigen receptors Concise review: humanized models of tumor immunology in the 21st century: convergence of cancer research and tissue engineering PSMA-specific CAR-engineered T cells eradicate disseminated prostate cancer in preclinical models Concise Review: Stem Cells in Pancreatic Cancer: From Concept to Translation 5T4-specific chimeric antigen receptor modification promotes the immune efficacy of cytokine-induced killer cells against nasopharyngeal carcinoma stem cell-like cells.Pancreatic cancer: Hurdles in the engineering of CAR-based immunotherapies.Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition.In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers.Evaluation of Intracellular Signaling Downstream Chimeric Antigen Receptors.Chimeric antigen receptor-engineered T cells for the treatment of metastatic prostate cancer.XactMice: humanizing mouse bone marrow enables microenvironment reconstitution in a patient-derived xenograft model of head and neck cancer A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors.Making Better Chimeric Antigen Receptors for Adoptive T-cell Therapy Toxicities of chimeric antigen receptor T cells: recognition and management.CAR-T cell therapy in gastrointestinal tumors and hepatic carcinoma: From bench to bedside.Role of immune cells in pancreatic cancer from bench to clinical application: An updated review Immunooncology: Can the Right Chimeric Antigen Receptors T-Cell Design Be Made to Cure All Types of Cancers and Will It Be Covered?Strategies to relieve immunosuppression in pancreatic cancer.Prospects for adoptive immunotherapy of pancreatic cancer using chimeric antigen receptor-engineered T-cells.T cell optimization for the treatment of pancreatic cancer.Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer.Treatment of solid tumors with chimeric antigen receptor-engineered T cells: current status and future prospects.Mouse models in oncoimmunology.Tumor-targeting domains for chimeric antigen receptor T cells.CAR T-cell therapy for pancreatic cancer.Modeling Natural Killer Cell Targeted Immunotherapies.Exploratory investigation of PSCA-protein expression in primary breast cancer patients reveals a link to HER2/neu overexpression.Co-stimulatory signaling determines tumor antigen sensitivity and persistence of CAR T cells targeting PSCA+ metastatic prostate cancer.Immune Evasion in Pancreatic Cancer: From Mechanisms to Therapy.Emerging trends in the immunotherapy of pancreatic cancer.CAR-T cells and combination therapies: What's next in the immunotherapy revolution?PSCA and MUC1 in non-small-cell lung cancer as targets of chimeric antigen receptor T cells.Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward.Characterization of a switchable chimeric antigen receptor platform in a pre-clinical solid tumor model.The Potential of CAR T Cell Therapy in Pancreatic Cancer

P2860

Q26795540-E6BA1A58-C5A0-4A9C-B0CA-19B08259DF7A Q27022477-7330CC9E-AE2C-4A06-854E-C23FD87D08B9 Q27339832-7531C67A-D17B-464B-B1B5-158C1B904B73 Q28081553-EA08AD72-ED3B-4D21-B6CE-A94FDF079EB1 Q33884816-5DC419AA-EB28-4908-A5E6-84DF4E8032B8 Q33940443-1A4917ED-3E9F-4C4B-87F5-3CC5D8B55955 Q34047618-0C8661D0-5BE6-48B1-B93E-5AD26591A1B6 Q34048101-C0E45A26-0C92-451E-A939-7CA6AA7344B5 Q35877585-FBB8D96C-E89D-4532-BF3C-ABC7D3156254 Q35980893-FF3FBA14-1248-4A5D-B3BB-C36A08FDF659 Q36185583-29A12A15-9DBD-4AC4-BC43-10067A2753AD Q36709308-4409853E-365B-4B2D-A159-96253A4187B4 Q36830759-FA137585-BC4C-4B39-B61E-6D61E6977410 Q37058104-19C358F3-6942-4582-9DCB-7FC5449D657D Q37559401-D0875A22-C453-4B86-8DDC-18BF6F64E812 Q37606102-CEB8353F-D776-476C-AC28-BB23036F0A4B Q37625303-A4F01DF8-CCD2-401C-9D53-24BF9B6EE672 Q38445328-BAA6DE85-85FB-4F6B-8AF3-B3A6B8C5A3C9 Q38608986-C8D86438-D0E6-483B-8D4E-C9C6E9EE6104 Q38638035-B80B0933-6CE1-4A26-BF1A-FB4B1178D7B4 Q38719148-2082E24E-1B20-4AF0-9E93-7CD4F67DE4A5 Q38770555-445B3688-BF32-4142-A53F-91FAEA56C0A3 Q38968582-7B15A571-625B-447F-AF68-3308A35694F4 Q39045535-91FE7EB7-0FB0-4EB9-A548-169521554B56 Q39202440-BE78A05C-7312-4D38-893A-E8B996A45ADA Q39239278-FCB4D9B0-3895-4175-8851-4CDB1F0CCCBE Q41551352-97673BA8-1635-4A01-B9BE-5A85870E7FDA Q47129409-B60065DA-D27A-44A8-A615-3B6B2B87191F Q47209071-AB2FCF2C-7E18-4439-80B7-784917ACDB73 Q47248817-BD601801-B0A3-48AC-A13E-BB3D236BC60A Q47285613-0FC26FDD-BA6F-42E3-8A8B-A0BC4BCA16C1 Q47920923-AF5E6C25-0457-4D26-BEC5-FE7D5CCC9F5E Q49280922-D98123CF-09B8-4262-A048-B4D0C8206215 Q55322285-5AAF165E-8C61-4148-A921-DE3AFDF43C5D Q57492021-E288195F-4BFB-43A5-8DA0-D523FEA530FB

P2860

A novel chimeric antigen receptor against prostate stem cell antigen mediates tumor destruction in a humanized mouse model of pancreatic cancer.

http://www.wikidata.org/entity/Q34729692

description

2014 nî lūn-bûn

@nan

2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

A novel chimeric antigen recep ...... se model of pancreatic cancer.

@ast

A novel chimeric antigen recep ...... se model of pancreatic cancer.

@en

A novel chimeric antigen recep ...... se model of pancreatic cancer.

@nl

type

label

A novel chimeric antigen recep ...... se model of pancreatic cancer.

@ast

A novel chimeric antigen recep ...... se model of pancreatic cancer.

@en

A novel chimeric antigen recep ...... se model of pancreatic cancer.

@nl

prefLabel

A novel chimeric antigen recep ...... se model of pancreatic cancer.

@ast

A novel chimeric antigen recep ...... se model of pancreatic cancer.

@en

A novel chimeric antigen recep ...... se model of pancreatic cancer.

@nl

P1433

Q34729692-2A61C577-B545-45DC-B181-9CFBA3A8CA23

P1476

Q34729692-4B95164E-8086-4FF6-B952-E7458A7D2A9A

P2093

Q34729692-006B6477-1578-41B8-990F-16320C7E5D39

Q34729692-019FE7B2-7B4A-484C-B778-3E26FB4C7493

Q34729692-3910D962-638F-4A17-8274-CA4BBE3C3DD8

Q34729692-5944610D-509C-4821-B06A-CD658A8333C8

Q34729692-69BDC2C0-B45E-497F-8214-805FE33AAD83

Q34729692-9492E520-C6AD-482A-9E1F-547DE7A7331B

Q34729692-949B40E6-BF62-4678-A2E7-86EA620F43A1

Q34729692-A0F89817-B350-4E89-9ACF-0351F4B02207

Q34729692-A5298C2F-221D-4FA0-909B-D20FBBFEF88C

Q34729692-C76ADDDF-DFCC-4614-9A50-A6D08061062D

P2860

Q34729692-0F0F73FB-1998-4248-B523-DD074315F1E6

Q34729692-17C2C19B-1593-4221-ABFB-9C15E84A45CE

Q34729692-23B634A8-4F9F-4D18-B51D-17CB81B0A65B

Q34729692-2CEC2D2F-C6EB-4B6D-84A4-45F475F94CD6

Q34729692-3745F02D-3929-47BB-B30F-71F7229EC689

Q34729692-3CC48C6F-9559-4B5A-8E65-E57EABDFA5CE

Q34729692-4480BA9B-478D-41BB-8B8D-81B53BDE7B06

Q34729692-5192F524-0020-42E3-978C-FF250D951363

Q34729692-5267F334-A3CC-4524-87C6-9FA0AEC919CE

Q34729692-599CD1D8-F063-4514-9CA4-CAEA30F8A779

P304

Q34729692-DC4AE1C7-25A4-4AE4-A64F-69FDFDD387A4

P31

Q34729692-867EC5CE-6C25-4A98-9C33-7C4DEFDA40A5

P356

Q34729692-CD74FE49-27B3-40BD-9962-E44323849B19

P433

Q34729692-31457CE4-0D70-4A0A-9E07-1A3E5C973040

P478

Q34729692-1510B48C-82F9-45B6-AB0F-4A9A779DE034

P50

Q34729692-9B674DF9-9C13-4E04-BEEF-4B9273D3EF82

Q34729692-E7F166CA-BD66-4F71-B9DB-035DDEE5C603

P577

Q34729692-62A76B11-C972-4E69-B7F2-809DFA14ED57

P5875

Q34729692-EA3C722E-5BEF-4A0A-8506-6D7A836A7627

P698

Q34729692-EA224AC9-6F63-4CD6-8BFB-43F7787EDFF3

P932

Q34729692-4EDCAB8F-4B47-4692-8F27-B96F204A9B42

P356

P1433

Human Gene Therapy

P1476

A novel chimeric antigen recep ...... use model of pancreatic cancer

@en

P2093

Anne M Miermont

http://www.w3.org/2001/XMLSchema#string

Daniel Abate-Daga

http://www.w3.org/2001/XMLSchema#string

Eric Tran

http://www.w3.org/2001/XMLSchema#string

Kiran H Lagisetty

http://www.w3.org/2001/XMLSchema#string

Luca Gattinoni

http://www.w3.org/2001/XMLSchema#string

Richard A Morgan

http://www.w3.org/2001/XMLSchema#string

Steven A Feldman

http://www.w3.org/2001/XMLSchema#string

Steven A Rosenberg

http://www.w3.org/2001/XMLSchema#string

William R Burns

http://www.w3.org/2001/XMLSchema#string

Yaroslav Teper

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer statistics, 2012

Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer

Reduced expression of PSCA, a member of the LY-6 family of cell surface antigens, in bladder, esophagus, and stomach tumors

A human memory T cell subset with stem cell-like properties

Targeting of tumor cells expressing the prostate stem cell antigen (PSCA) using genetically engineered T-cells

Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1

Inducible apoptosis as a safety switch for adoptive cell therapy

Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2

B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells

Discovery of new markers of cancer through serial analysis of gene expression: prostate stem cell antigen is overexpressed in pancreatic adenocarcinoma.

P304

1003-1012

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1089/HUM.2013.209

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

25

http://www.w3.org/2001/XMLSchema#string

P50

Nicholas P. Restifo

P577

2014-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

261325258

http://www.w3.org/2001/XMLSchema#string

P698

24694017

http://www.w3.org/2001/XMLSchema#string

P932

4270113

http://www.w3.org/2001/XMLSchema#string